Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revvity, Inc. (NYSE: RVTY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Revvity, a Massachusetts-incorporated health science and diagnostics company and member of the S&P 500 index, uses these filings to report material events, financial results, and governance changes related to its operations and securities.
Recent Form 8-K filings illustrate how Revvity communicates with the market. The company files 8-Ks to furnish earnings press releases for its quarterly results, to announce preliminary expectations for financial performance, and to provide presentation materials for major investor conferences such as the J.P. Morgan Healthcare Conference. Other 8-Ks disclose board and executive appointments and confirm details about its registered securities, including common stock and notes listed on the New York Stock Exchange.
Through its filings and accompanying earnings materials, Revvity explains the use of non-GAAP financial measures such as adjusted earnings per share, adjusted operating income, and organic revenue growth. The company describes how management uses these measures to evaluate operating performance, benchmark results, and inform compensation decisions, while also outlining the limitations of non-GAAP metrics and providing reconciliations to GAAP figures.
On this page, Stock Titan surfaces Revvity’s SEC filings with real-time updates from EDGAR and AI-powered summaries that clarify the purpose and implications of each document. Users can quickly understand the key points of quarterly results, changes in guidance, capital allocation actions, and governance updates without reading every line of the original filings. Access to these filings, including Form 8-Ks and related exhibits, helps investors, analysts, and researchers track how Revvity reports its financial condition, segment performance, and significant corporate events over time.
REVVITY, INC. executive Maxwell Krakowiak, Senior Vice President and Chief Financial Officer, reported multiple equity transactions dated February 4, 2026. He surrendered 708 shares of common stock at
He also acquired 7,262 time-based restricted stock units at no cost, bringing his directly held common stock to 18,771 shares. In addition, he received a non-qualified stock option for 20,771 shares at an exercise price of
Revvity, Inc. Senior Vice President and Chief Commercial Officer Miriame Victor reported equity compensation activity on February 4, 2026. She received 5,401 time-based restricted stock units at no cost and was granted a nonqualified stock option for 15,449 shares at an exercise price of $103.395 per share.
To cover tax withholding on previously granted restricted stock units that vested the same day, 536 common shares were surrendered at a price of $101.13 per share. After these transactions, she directly holds 19,153 shares of common stock and 15,449 options, all vesting in three equal annual installments beginning on the first anniversary of the grant date.
Revvity, Inc. insider plans to sell common stock under Rule 144. A holder filed to sell 25,525 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $2,557,886.18, when 113,375,621 shares were outstanding. The shares were acquired by exercising a stock option originally granted on 02/05/2019, with the option exercised and paid in cash on 02/05/2026.
RVTY has a planned insider sale of common stock under Rule 144. The notice covers 12,717 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,274,382.22.
The shares relate to a stock option granted on 02/05/2019 and acquired on 02/05/2026, with the purchase price paid in cash. The filing notes that 113,375,621 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Revvity, Inc. executive Tajinder S. Vohra exercised and sold stock options in a planned transaction. On 02/02/2026, Vohra exercised a nonqualified stock option for 5,756 shares of common stock at
The option, which vested in three equal annual installments beginning on February 5, 2020, was fully exercised, leaving 0 derivative securities. After the sale, Vohra directly owned 10,442 shares of Revvity common stock. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on February 20, 2025. Vohra serves as Senior Vice President, Global Operations.
A holder of RVTY common stock has filed a Rule 144 notice to sell 5,756 shares through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026, with an aggregate market value of 601502.00.
The issuer had 113,375,621 shares of common stock outstanding. The shares to be sold were acquired as a result of stock options granted on 02/05/2019 and exercised for cash on 02/02/2026.
Revvity, Inc. furnished an update on its performance by announcing financial results for the fourth quarter and full fiscal year ended December 28, 2025. The company released these results through a press release dated February 2, 2026, which is provided as Exhibit 99.1 and treated as furnished, not filed, under securities law.
Revvity, Inc. filed a current report describing upcoming financial communications and an investor presentation. The company announced preliminary expectations for certain financial results for its fourth quarter ended December 28, 2025 and said it will release full fourth quarter and full year 2025 financial results on February 2, 2026. These details are contained in a press release furnished as an exhibit.
The filing also notes that President and CEO Dr. Prahlad Singh is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with the presentation materials furnished as a separate exhibit. Both the press release and the presentation are being furnished rather than filed, which limits their exposure to certain Exchange Act liabilities.
Revvity, Inc. executive Anita Gonzales, Vice President and Chief Accounting Officer, reported a small insider stock transaction. On 12/15/2025, 25 shares of common stock were disposed of at $100.49 per share, coded as an "F" transaction.
According to the footnote, these shares were surrendered to satisfy tax withholding obligations upon vesting of restricted stock units originally granted on 12/15/2023 under her Restricted Stock Unit Agreement. Following this automatic tax-withholding event, she beneficially owns 4,315 shares of Revvity common stock directly.
Revvity, Inc. (RVTY): Schedule 13G/A — Janus Henderson Group plc reported beneficial ownership of 7,627,259 American Depositary Shares, representing 6.6% of the class. The filer reported 0 sole voting and dispositive power and 7,627,259 shared voting and dispositive power. The filing is certified as being made in the ordinary course and not for the purpose of changing or influencing control.
Separately, the filing notes that Janus Henderson Investors US LLC (JHIUS) may be deemed to beneficially own 7,588,607 shares, or 6.5%, with shared voting and dispositive power and no sole powers. The report identifies the reporting person’s type as IA, HC and includes a standing power of attorney for signature authority.